See more : DTE Energy Company 2021 Series (DTG) Income Statement Analysis – Financial Results
Complete financial analysis of Vir Biotechnology, Inc. (VIR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Vir Biotechnology, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- APM Industries Limited (APMIN.BO) Income Statement Analysis – Financial Results
- Beekay Steel Industries Limited (BEEKAY.BO) Income Statement Analysis – Financial Results
- SEDCO Capital REIT Fund (4344.SR) Income Statement Analysis – Financial Results
- Spring Airlines Co., Ltd. (601021.SS) Income Statement Analysis – Financial Results
- City Online Services Limited (CITYONLINE.BO) Income Statement Analysis – Financial Results
Vir Biotechnology, Inc. (VIR)
About Vir Biotechnology, Inc.
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 86.18M | 1.58B | 1.09B | 67.25M | 711.00K | 868.00K | 149.00K |
| Cost of Revenue | 2.77M | 146.32M | 65.87M | 301.58M | 148.47M | 100.23M | 62.51M |
| Gross Profit | 83.42M | 1.43B | 1.02B | -234.33M | -147.76M | -99.36M | -62.36M |
| Gross Profit Ratio | 96.79% | 90.74% | 93.94% | -348.48% | -20,782.14% | -11,447.12% | -41,854.36% |
| Research & Development | 589.67M | 474.65M | 448.01M | 302.41M | 148.47M | 100.23M | 62.51M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 70.94M | 37.60M | 29.13M | 21.69M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 174.05M | 161.76M | 160.79M | 70.94M | 37.60M | 29.13M | 21.69M |
| Other Expenses | 0.00 | -35.33M | -8.35M | -9.12M | -7.38M | -212.00K | 83.00K |
| Operating Expenses | 767.72M | 601.09M | 600.45M | 364.23M | 178.69M | 119.56M | 81.65M |
| Cost & Expenses | 770.49M | 747.40M | 666.32M | 364.23M | 178.69M | 119.56M | 81.65M |
| Interest Income | 86.99M | 28.09M | 439.00K | 2.84M | 8.51M | 2.54M | 638.00K |
| Interest Expense | 0.00 | 183.15M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 19.45M | 15.49M | 11.98M | 8.81M | 4.52M | 2.76M | 432.00K |
| EBITDA | -664.85M | 833.07M | 420.75M | -289.80M | -173.46M | -115.94M | -81.07M |
| EBITDA Ratio | -771.47% | 59.74% | 26.01% | -441.64% | -25,032.21% | -13,356.68% | -54,406.04% |
| Operating Income | -684.31M | 833.07M | 276.89M | -296.98M | -177.98M | -118.69M | -81.50M |
| Operating Income Ratio | -794.04% | 52.71% | 25.47% | -441.64% | -25,032.21% | -13,674.19% | -54,695.97% |
| Total Other Income/Expenses | 56.11M | -78.79M | 129.05M | -1.63M | 3.45M | 2.33M | 721.00K |
| Income Before Tax | -628.19M | 754.28M | 549.80M | -298.61M | -174.53M | -116.36M | -80.78M |
| Income Before Tax Ratio | -728.93% | 47.72% | 50.58% | -444.06% | -24,546.98% | -13,405.99% | -54,212.08% |
| Income Tax Expense | -13.08M | 238.44M | 21.22M | 54.00K | 154.00K | -480.00K | -10.92M |
| Net Income | -615.06M | 515.84M | 528.58M | -298.67M | -174.68M | -115.88M | -69.85M |
| Net Income Ratio | -713.69% | 32.64% | 48.62% | -444.14% | -24,568.64% | -13,350.69% | -46,880.54% |
| EPS | -4.59 | 3.89 | 4.07 | -2.51 | -1.62 | -1.20 | -0.72 |
| EPS Diluted | -4.59 | 3.83 | 3.96 | -2.51 | -1.62 | -1.20 | -0.72 |
| Weighted Avg Shares Out | 134.13M | 132.61M | 129.88M | 119.16M | 107.65M | 96.91M | 96.91M |
| Weighted Avg Shares Out (Dil) | 134.13M | 134.81M | 133.44M | 119.16M | 107.65M | 96.91M | 96.91M |
Vir Biotechnology, Inc. (VIR) Reports Q1 Loss, Tops Revenue Estimates
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2024 Financial Results
Vir Biotechnology to Participate in the BofA Securities Healthcare Conference 2024
What Makes Vir Biotechnology (VIR) a New Buy Stock
Vir Biotechnology Announces Nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D.
Vir Biotechnology to Provide Business Update and Report First Quarter 2024 Financial Results on May 2, 2024
From Six Figures to Seven: 3 Biotech Stocks Set to Make Millionaires
Billionaire's Biotech Bets: 3 Stocks Dominating Bill Gates' Portfolio
Vir Biotechnology: Making Progress In Hepatitis B And Hepatitis Delta
3 Highly Rated Biotech Stocks to Buy for 300% Gains
Source: https://incomestatements.info
Category: Stock Reports